Stock listing

NASDAQ:ZBIO Zenas BioPharma, Inc. Stock

Home listing (NASDAQ) of Zenas BioPharma, Inc.

Follow Zenas BioPharma, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ZBIO

$23.85 USD -2.57 (-9.7%)

Close on Nov 20, 2026

Past year -31.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$23.78 – $25.64 USDNov 20, 2026
Volume
579,893 sharesNov 20, 2026
Market cap
$1.62B USDAt the close on Nov 20, 2026 · price × 67.82M shares outstanding
52-week range
$13.50 – $44.60 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$17.84M USDMedian day 527,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Zenas BioPharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ZBIO · Home$23.85 USD-2.57 (-9.7%)579,893$24.75$25.64$23.78$26.42Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ZBIO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$23.85-2.57-9.7%$24.75$25.64$23.78579,893
$26.42-1.33-4.8%$27.84$28.84$26.29480,035
$27.75-0.18-0.6%$27.93$28.13$27.00524,652
$27.93-0.08-0.3%$27.79$28.35$27.50630,393
$28.01+0.37+1.3%$27.50$28.18$26.89304,825
$27.64-1.06-3.7%$28.18$28.75$27.42750,771
$28.70+0.12+0.4%$28.95$29.51$28.50306,259
$28.58+0.010.0%$28.22$29.89$28.11304,669
$28.57+0.31+1.1%$28.75$30.02$27.80634,856
$28.26+2.33+9.0%$26.21$28.44$25.94543,966
$25.93-2.53-8.9%$28.10$28.49$25.79822,021
$28.46+0.08+0.3%$29.27$29.80$28.01800,738
$28.38+0.76+2.8%$27.85$29.05$27.84572,811
$27.62-0.77-2.7%$28.47$28.81$27.15408,282
$28.39-0.37-1.3%$28.35$29.11$27.91358,069
$28.76-0.010.0%$29.08$29.60$28.37373,024
$28.77+1.47+5.4%$27.10$29.07$27.03391,455
$27.30+0.06+0.2%$27.09$28.23$26.72581,011
$27.24+0.37+1.4%$27.18$28.17$26.68371,646
$26.87-1.36-4.8%$28.00$28.33$26.73377,500
$28.23+0.15+0.5%$27.95$28.83$27.51406,000
$28.08-0.10-0.4%$28.47$29.44$27.90484,000
$28.18+1.47+5.5%$26.38$29.71$26.38549,000
$26.71+1.87+7.5%$25.08$27.55$25.08696,500
$24.84-0.56-2.2%$25.36$25.96$24.51661,700
$25.40+0.54+2.2%$24.96$25.94$24.25471,900
$24.86-0.30-1.2%$24.82$26.49$24.39425,100
$25.16-1.24-4.7%$26.11$27.00$25.04519,700
$26.40-0.86-3.2%$26.93$27.49$26.30602,500
$27.26+1.02+3.9%$26.18$27.64$26.18429,600
$26.24-1.94-6.9%$27.98$27.98$25.51557,500
$28.18+1.24+4.6%$26.89$28.86$26.78509,100
$26.94-0.89-3.2%$27.87$28.14$26.28357,600
$27.83-0.465-1.6%$28.47$29.06$27.771,131,900
$28.30+0.355+1.3%$28.47$29.20$27.841,513,600
$27.94+0.97+3.6%$26.89$29.23$26.55881,900
$26.97+0.21+0.8%$26.99$28.38$26.54623,200
$26.76-0.79-2.9%$27.30$27.62$26.18440,600
$27.55+0.60+2.2%$27.07$28.23$26.46615,300
$26.95-0.55-2.0%$27.44$28.50$25.90747,800
$27.50-2.13-7.2%$29.51$30.12$25.70962,900
$29.63-3.42-10.3%$33.09$33.09$29.53525,100
$33.05+0.50+1.5%$32.55$33.84$32.15452,800
$32.55+1.05+3.3%$31.62$33.19$31.00414,500
$31.50-0.47-1.5%$32.04$32.04$31.252,515,200
$31.97-0.35-1.1%$32.78$33.48$31.55527,800
$32.32+0.39+1.2%$31.89$33.23$31.59746,400
$31.93+0.02+0.1%$32.06$32.06$30.27716,000
$31.91+0.79+2.5%$31.00$32.00$30.66634,600
$31.12+0.02+0.1%$31.48$32.32$31.12421,700
$31.10-1.19-3.7%$31.88$31.89$30.73646,900
$32.29-0.76-2.3%$33.02$33.53$32.09385,400
$33.05+0.17+0.5%$32.65$33.84$32.31441,200
$32.88-0.04-0.1%$32.66$33.29$32.38452,700
$32.92-0.21-0.6%$33.42$33.66$32.37515,100
$33.13+1.15+3.6%$32.21$33.40$31.93757,500
$31.98-0.34-1.1%$32.20$32.73$31.55432,300
$32.32+1.05+3.4%$31.51$32.77$29.88527,700
$31.27-1.35-4.1%$32.27$32.38$31.19439,100
$32.62-0.42-1.3%$32.81$33.69$32.38659,000
$33.04-0.73-2.2%$33.80$33.99$31.91651,600
$33.77+2.12+6.7%$32.00$33.78$31.65633,583
$31.65-0.64-2.0%$32.40$32.48$30.95481,882
$32.29+0.67+2.1%$31.83$32.79$31.45808,700
$31.62+0.37+1.2%$30.72$32.20$29.501,172,500
Ticker
NASDAQ:ZBIO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

Zenas BioPharma to Host Virtual R&D Event

Oct 6, 2026

Closed $26.94 (-3.2%) on Oct 6, 2026

All Zenas BioPharma, Inc. news

Zenas BioPharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 35 in all · newest Nov 18, 2026 · oldest 2025
Decks
4 decks · latest 2026

Where Zenas BioPharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ZBIO · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ZBIOBOATSUnited StatesUSD

Valuation

EV/sales 114× against a median of 50.8×: 9th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.26B USD
P/E
Loss
EV/sales
114×
EV/EBITDA
Negative EBITDA
Price/book
7.6×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
1.1×
Beta vs S&P 500
1.05

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Zenas BioPharma, Inc. · NASDAQ:ZBIOUS$1.62BUS$1.26Bn/a114×n/a7.6×n/a1.1×1.05
Neuren Pharmaceuticals Limited · ASX:NEUUS$1.76BUS$1.57B87.3×36.7×108×8.0×47.1%0.0×n/a
Stoke Therapeutics, Inc. · NASDAQ:STOKUS$1.75BUS$1.43Bn/a50.8×n/a5.0×−862.1%0.0×0.78
First Tracks Biotherapeutics, Inc. · NASDAQ:TRAXUS$1.75BUS$1.60Bn/an/an/a11.6×n/a0.0×1.80
Maze Therapeutics, Inc. · NASDAQ:MAZEUS$1.74BUS$1.39Bn/a69.6×n/a4.1×−757.4%0.1×0.66
Lycia Therapeutics, Inc. · NASDAQ:LYCAUS$1.72BUS$1.60Bn/a237×n/an/a−540.9%n/an/a
Hitgen Inc. Class A · SSE:688222US$1.56BUS$1.44B66.5×13.6×n/a6.5×22.1%0.2×n/a
Recursion Pharmaceuticals, Inc. · NASDAQ:RXRXUS$1.53BUS$987.7Mn/a14.5×n/a1.7×−697.1%0.0×2.83
Alvotech · NASDAQ:ALVOUS$1.47BUS$2.78Bn/a5.7×31.4×n/a−36.5%n/a0.90
ABL Bio, Inc. · KRX:298380US$1.47BUS$1.34Bn/a52.7×n/a11.5×−229.4%0.0×n/a
Mesoblast Limited · ASX:MSBUS$1.46BUS$1.42Bn/a82.5×n/a2.4×−593.9%0.2×n/a
Median of the othersUS$1.64BUS$1.44B76.9×50.8×69.5×5.8×−540.9%0.0×0.90

Forecasts

7 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
47.88 USD · Analysts' mean
EPS, year to Dec 2026
-5.94 · 2 analysts
Revenue, year to Dec 2026
20.38M · 6 analysts

Team and board

Officers

OfficerRole
Lonnie MoulderChief Executive Officer and Chairman of the Board of Directors
Joe FarmerPresident and Chief Operating Officer
Jerald KornChief Legal & Strategy Officer
Caroline ChevalierChief Administrative Officer
Haley LakenChief Scientific Officer
Heinrich SchliekerChief Technical Officer
Lisa von MoltkeHead of Research and Development and Chief Medical Officer

Board

DirectorRole
Lonnie MoulderChief Executive Officer and Chairman of the Board of Directors
Christy OligerBoard Member
Hongbo LuBoard Member
Jake NunnBoard Member
James BoylanBoard Member
John OrloffBoard Member
Patricia AllenBoard Member
Patrick EnrightBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−8.9%
Q2 2026Aug 13, 2026 · Before open−6.7%
Q1 2026May 13, 2026−1.4%
Q4 2025Mar 16, 2026 · Before open−3.4%
Q3 2025Nov 12, 2025 · Before open+1.7%
Q2 2025Aug 12, 2025 · Before open+6.7%
Q1 2025May 15, 2025 · Before open+12.2%
Q4 2024Feb 26, 2025−5.8%
Q3 2024Nov 12, 2024 · Before open−3.1%
Q2 2024Aug 22, 2024 · After close

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (2026)Technical24 slides2026
Merger or Acquisition (October 2025)Merger or acquisition49 slidesOct 8, 2025
Investor Presentation (June 2025)Investor deck25 slidesJun 4, 2025
Investor Presentation (December 2024)Investor deck36 slidesDec 2, 2024

Open Decks

Financings

RaiseDate
Private placement of common stock
Announced: about US$120M · US$19 a share · Jefferies +1
Dealers: Jefferies (co-lead), Evercore ISI (co-lead)
Insiders: Certain directors and officers of the Company participate at a price of $20.85 per share
Oct 8, 2025
Royalty funding (5.5% royalty on worldwide net sales of obexelimab)
Announced: up to US$300M · Evercore
Dealers: Evercore
Buyers: Royalty Pharma plc (up to $300 million in funding in exchange for a 5.5% royalty on worldwide net sales of obexelimab)
Use of proceeds: Obexelimab development and a potential IgG4-RD commercial launch in the first half of 2027, subject to FDA approval
Sep 2, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$17.00 a share on Sep 12, 2024.

Price
US$17.00 a share
Shares offered
13,235,294 shares of common stock
Offering size
US$225 million
Underwriters' option
Up to 1,985,294 more shares
Listing
ZBIO on the Nasdaq Global Select Market
Underwriters
MORGAN STANLEY, JEFFERIES, CITIGROUP, GUGGENHEIM SECURITIES · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceJan 25, 2024
Filed publiclyAug 22, 2024
Amended onceSep 6, 2024
Shares registered with an exchangeSep 10, 2024
Declared effective by the SECSep 12, 2024
Final prospectus, with the priceSep 13, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Sep 13, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue10.0M5.00M50.0M0
Cost of revenue56.0K139.1M113.0K61.7M
Gross profit10.0M-134.1M50.0M-61.7M
Research and development168.1M139.1M60.0M62.7M
Selling, general and administrative53.3M28.8M17.1M12.8M
Operating income-383.1M-163.9M-37.1M-76.2M
Depreciation and amortization56.0K137.0K113.0K78.0K
EBITDA-383.0M-163.8M-37.0M-76.1M
Interest expense7.33M0
Income before tax-377.8M-156.6M-36.8M-119.3M
Income tax-79.0K429.0K301.0K
Net income-377.7M-157.0M-37.1M-119.3M
Earnings per share, basic-8.44-11.89-24.25-3.11
Earnings per share, diluted-8.44-11.89-24.25

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents110.6M319.7M56.9M67.2M
Short-term investments232.6M31.0M0
Current assets351.2M355.9M59.8M68.4M
Property, plant and equipment34.0K185.0K193.0K
Total assets383.6M370.0M68.2M74.6M
Accounts payable7.11M17.1M5.40M5.82M
Current liabilities62.6M57.3M23.3M26.0M
Long-term debt78.6M20.3M
Total debt78.6M1.00M21.1M1.53M
Total liabilities141.5M57.5M43.8M266.9M
Shareholders' equity242.1M312.5M-225.7M-192.3M
Shares outstanding54.5M41.8M1.58M38.3M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-172.3M-119.7M-30.5M-65.7M
Capital spending-18.0K-131.0K-17.0K-2.20M
Free cash flow-172.4M-119.8M-30.5M-67.8M
Cash from investing-251.9M-30.6M-17.0K-2.20M
Cash from financing215.3M413.0M20.1M59.4M
Share buybacks276.0K
Change in cash-209.2M262.9M-10.4M-8.50M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 6, 2026Current reportSEC
424B5 · ProspectusNov 6, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
8-K · Current reportOct 13, 2026Current reportSEC
S-3ASR · Registration statementSep 11, 2026Offer documentSEC
S-8 · Registration statement for employee plansSep 11, 2026Offer documentSEC
All 196 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeSep 8, 2026Big-stake noticeSEC
3 · Initial statement of ownershipSep 8, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedSep 8, 2026Big-stake noticeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 2, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 19, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 17, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
SCHEDULE 13D · Big-stake noticeMay 5, 2026Big-stake noticeSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 2, 2026Big-stake noticeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
8-K · Current reportMar 31, 2026Material contractSEC
424B5 · ProspectusMar 30, 2026Offer documentSEC
424B5 · ProspectusMar 30, 2026Offer documentSEC
FWP · Free writing prospectusMar 27, 2026Offer documentSEC
FWP · Free writing prospectusMar 27, 2026Offer documentSEC
424B5 · ProspectusMar 26, 2026Offer documentSEC
424B5 · ProspectusMar 26, 2026Offer documentSEC
FWP · Free writing prospectusMar 26, 2026Offer documentSEC
DEFA14A · Additional proxy materialMar 16, 2026Meeting noticeSEC
ARS · Annual report to shareholdersMar 16, 2026Annual reportSEC
DEF 14A · Proxy statementMar 16, 2026Meeting noticeSEC
S-8 · Registration statement for employee plansMar 16, 2026Offer documentSEC
10-K · Annual reportMar 16, 2026Annual reportSEC
8-K · Current reportMar 16, 2026ResultsSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
8-K · Current reportFeb 13, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
424B7 · ProspectusJan 28, 2026Offer documentSEC
SCHEDULE 13D · Big-stake noticeJan 14, 2026Big-stake noticeSEC
4 · Change in ownershipJan 9, 2026Insider tradeSEC
8-K · Current reportJan 5, 2026ResultsSEC
S-8 · Registration statement for employee plansDec 19, 2025Offer documentSEC
8-K · Current reportDec 15, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportOct 27, 2025Current reportSEC
S-3ASR · Registration statementOct 21, 2025Offer documentSEC
3 · Initial statement of ownershipOct 15, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 15, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 14, 2025Big-stake noticeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 14, 2025Big-stake noticeSEC
4 · Change in ownershipOct 14, 2025Insider tradeSEC
4 · Change in ownershipOct 9, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 9, 2025Big-stake noticeSEC
4 · Change in ownershipOct 9, 2025Insider tradeSEC
4 · Change in ownershipOct 9, 2025Insider tradeSEC
S-3ASR · Registration statementOct 8, 2025Offer documentSEC
8-K · Current reportOct 8, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedSep 8, 2025Big-stake noticeSEC
8-K · Current reportSep 2, 2025Acquisition or disposalSEC
S-8 · Registration statement for employee plansAug 12, 2025Offer documentSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2025Big-stake noticeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
8-K · Current reportJun 12, 2025Management or board changeSEC
SCHEDULE 13D · Big-stake noticeJun 6, 2025Big-stake noticeSEC
8-K · Current reportJun 4, 2025Current reportSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
4/A · Change in ownership, amendedApr 28, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
4 · Change in ownershipApr 17, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 1, 2025Big-stake noticeSEC
3 · Initial statement of ownershipMar 21, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 11, 2025Offer documentSEC
10-K · Annual reportMar 11, 2025Annual reportSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
8-K · Current reportFeb 5, 2025ResultsSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
4 · Change in ownershipDec 4, 2024Insider tradeSEC
8-K · Current reportDec 2, 2024Current reportSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G · Big-stake noticeOct 21, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeSep 25, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeSep 23, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeSep 23, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeSep 23, 2024Big-stake noticeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 18, 2024Insider tradeSEC
4 · Change in ownershipSep 18, 2024Insider tradeSEC
SEC STAFF LETTERSep 18, 2024Other filingsSEC
4/A · Change in ownership, amendedSep 17, 2024Insider tradeSEC
4/A · Change in ownership, amendedSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
4 · Change in ownershipSep 16, 2024Insider tradeSEC
S-8 · Registration statement for employee plansSep 16, 2024Offer documentSEC
8-K · Current reportSep 16, 2024Current reportSEC
424B4 · ProspectusSep 13, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 13, 2024Other filingsSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 12, 2024Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringSep 12, 2024Offer documentSEC
CERT · Exchange's certificate of listingSep 12, 2024Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeSep 10, 2024Other filingsSEC
CORRESP · Letter to the SECSep 10, 2024Other filingsSEC
CORRESP · Letter to the SECSep 10, 2024Other filingsSEC
S-1/A · Registration statement, amendedSep 6, 2024Offer documentSEC
CORRESP · Letter to the SECAug 27, 2024Other filingsSEC
S-1 · Registration statementAug 22, 2024Offer documentSEC
DRSLTR · Letter to the SEC with a draftJul 25, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 24, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftJul 16, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 5, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftJun 26, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedJun 26, 2024Offer documentSEC
UPLOAD · Letter from the SECJun 18, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftJun 14, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedJun 14, 2024Offer documentSEC
UPLOAD · Letter from the SECMay 28, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftMay 15, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedMay 15, 2024Offer documentSEC
DMay 14, 2024Other filingsSEC
SEC STAFF LETTERFeb 27, 2024Other filingsSEC
UPLOAD · Letter from the SECFeb 21, 2024Other filingsSEC
DRS · Draft registration statementJan 25, 2024Offer documentSEC
DNov 15, 2022Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Zenas BioPharma, Inc.’s releases · as of Nov 16, 2026

Common shares
67,817,793
Fully diluted
68,051,793

Fully diluted

LineSharesAs of
Common shares67,817,793Oct 30, 2026
Options and RSUs234,000Nov 16, 2026

Warrants and options

Lot
Stock options · US$27.93 · expire about Nov 2036
RSUs · expiry not stated

Share count over time

CountShares
Oct 30, 202667,817,793

Open Cap table

Shareholders

Institutions

HolderSharesValueChange vs Jun 30Filed
Fidelity9.79MUS$264M+286KNov 10, 2026
Wellington8.09MUS$218M+6.5MNov 16, 2026
Sr One Capital Management, LP5.04MUS$136MNo changeNov 16, 2026
NEA Management Company, LLC4.02MUS$109MNo changeNov 16, 2026
BlackRock3.33MUS$89.9M+646KNov 13, 2026
Federated Hermes, Inc.3.11MUS$83.8M−9,497Nov 12, 2026
Capital Group2.93MUS$78.9M+422KNov 12, 2026
Enavate Sciences Gp, LLC2.92MUS$78.7M−1MNov 16, 2026
Vanguard2.47MUS$66.5M+513KNov 13, 2026
Polar Capital Holdings Plc2.41MUS$64.9M−7,398Nov 16, 2026
Show 50 holders
HolderSharesValueChange vs Jun 30Filed
Royalty Pharma Sub-Manager, LLC2.39MUS$64.4MNo changeNov 13, 2026
Fairmount Funds Management LLC2.37MUS$64M+12,333Nov 16, 2026
State Street1.88MUS$50.8M−172KNov 12, 2026
Nvp Associates, LLC1.84MUS$49.6MNo changeNov 13, 2026
T. Rowe Price1.09MUS$29.3M−139KNov 16, 2026
AllianceBernstein1.06MUS$28.6M−42,849Nov 16, 2026
Geode Capital1.06MUS$28.6M+178KNov 6, 2026
Two Sigma833KUS$22.5M+18,138Nov 16, 2026
EcoR1 Capital, LLC790KUS$21.3MNo changeNov 16, 2026
Goldman Sachs775KUS$20.9M+503KNov 16, 2026
Bank of America683KUS$18.4M−548KNov 16, 2026
Candriam S.C.A.655KUS$17.7MNewNov 3, 2026
Woodline Partners LP591KUS$15.9M+430Nov 16, 2026
ArrowMark Colorado Holdings LLC528KUS$14.2M−45,342Nov 16, 2026
Rock Springs Capital Management LP502KUS$13.5MNo changeNov 16, 2026
Balyasny Asset Management L.P.491KUS$13.2M−85,865Nov 16, 2026
UBS474KUS$12.8M+258KNov 16, 2026
NEXTBio Capital Management LP427KUS$11.5MNo changeNov 13, 2026
Vestal Point Capital, LP395KUS$10.7M+30,000Nov 16, 2026
Schwab383KUS$10.3M+81,257Nov 16, 2026
Northern Trust350KUS$9.45M+69,276Nov 16, 2026
BNP Paribas350KUS$9.44M+198KNov 12, 2026
Silverarc Capital Management, LLC334KUS$9.01M−176KNov 12, 2026
Barclays253KUS$6.81M+137KNov 6, 2026
Jennison Associates LLC242KUS$6.53M−72,097Nov 13, 2026
Pivotal bioVenture Partners Investment Advisor LLC233KUS$6.29M−258KNov 13, 2026
Millennium194KUS$5.23M−466KNov 16, 2026
Morgan Stanley190KUS$5.12M+54,686Nov 13, 2026
Voleon Capital Management LP170KUS$4.58M+2,542Nov 16, 2026
Marshall Wace, LLP167KUS$4.5M−157KNov 13, 2026
Walleye Capital LLC120KUS$3.22M−89,499Nov 13, 2026
Invesco112KUS$3.01M+92,699Nov 12, 2026
Atom Investors LP111KUS$2.99M+73,574Nov 16, 2026
Seven Grand Managers, LLC100KUS$2.7MNo changeNov 16, 2026
BNY99,186US$2.68M+28,709Nov 5, 2026
Point72 Asset Management, L.P.98,787US$2.66M+82,651Nov 16, 2026
Sio Capital Management, LLC95,457US$2.57M−113KNov 16, 2026
Birchview Capital, LP93,380US$2.52M−221Nov 13, 2026
Alps Advisors Inc86,369US$2.33M+22,694Nov 2, 2026
Jump Financial, LLC83,980US$2.26M+32,958Nov 13, 2026

This page holds 50 of 146 holders. Open Shareholders

Funds

HolderSharesValueChangeAs of
Vanguard Health Care Fund2.94MUS$92.3MNewJul 31, 2026
SMALLCAP World Fund Inc2.43MUS$61.8MNo changeJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.35MUS$34.2M+443KJun 30, 2026
Federated Hermes Kaufmann Fund1.33MUS$41.8MNo changeJul 31, 2026
Select Health Care Portfolio1.08MUS$19.9MNo changeMay 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund1.01MUS$18.6M+279KMay 31, 2026
Fidelity Small Cap Growth Fund989KUS$31.1MNo changeJul 31, 2026
Federated Hermes Kaufmann Small Cap Fund897KUS$28.2MNo changeJul 31, 2026
Vanguard Total Stock Market Index Fund891KUS$22.6MNo changeJun 30, 2026
iShares Russell 2000 ETF745KUS$18.9M+175KJun 30, 2026
Show 50 holders
HolderSharesValueChangeAs of
Fidelity Stock Selector Small Cap Fund663KUS$20.8M+112KJul 31, 2026
Fidelity Small Cap Growth K6 Fund531KUS$16.7MNo changeJul 31, 2026
Fidelity Advisor Health Care Fund500KUS$15.7MNo changeJul 31, 2026
Fidelity Advisor Biotechnology Fund492KUS$15.5M−119KJul 31, 2026
AB Small Cap Growth Portfolio468KUS$11.9M+69,909Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.466KUS$11.8M+238KJun 30, 2026
Vanguard Extended Market Index Fund436KUS$11.1M+114KJun 30, 2026
Fidelity Series Small Cap Opportunities Fund391KUS$12.3M−25,200Jul 31, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund385KUS$9.77MNewJun 30, 2026
Select Biotechnology Portfolio380KUS$7MNo changeMay 31, 2026
Fidelity Small Cap Index Fund312KUS$9.8M+78,875Jul 31, 2026
Fidelity Small Cap Discovery Fund282KUS$8.88M+22,791Jul 31, 2026
iShares Russell 2000 Growth ETF268KUS$6.79MNewJun 30, 2026
Fidelity Series Small Cap Discovery Fund247KUS$7.75M+19,575Jul 31, 2026
iShares Biotechnology ETF224KUS$5.7M+48,505Jun 30, 2026
Meridian Contrarian Fund223KUS$5.65M−21,000Jun 30, 2026
VIP Health Care Portfolio185KUS$4.7MNo changeJun 30, 2026
Fidelity Series Small Cap Core Fund163KUS$5.13M+6,200Jul 31, 2026
Fidelity Extended Market Index Fund148KUS$2.72M−1,135May 31, 2026
SmallCap Growth Fund I140KUS$4.4M+27,158Jul 31, 2026
Schwab U.S. Small-Cap ETF135KUS$2.48M−2,180May 31, 2026
Small Cap Core Portfolio122KUS$3.1MNewJun 30, 2026
Vanguard Russell 2000 Index Fund121KUS$2.22M+26,993May 31, 2026
The Hartford Healthcare Fund109KUS$3.42MNewJul 31, 2026
Strategic Advisers U.S. Total Stock Fund104KUS$1.91M+43,767May 31, 2026
Fidelity U.S. Equity Central Fund100KUS$2.54MNo changeJun 30, 2026
iShares Micro-Cap ETF95,784US$2.43M+36,503Jun 30, 2026
Meridian Small Cap Growth Fund84,524US$2.15MNo changeJun 30, 2026
Schwab Small-Cap Index Fund69,038US$2.17M+17,433Jul 31, 2026
SMALLCAP World Fund68,912US$1.75MNewJun 30, 2026
Vanguard U.S. Momentum Factor ETF68,019US$1.25M−10,707May 31, 2026
Fidelity Fundamental Small-Mid Cap ETF66,271US$2.08M+9,274Jul 31, 2026
Invesco Dorsey Wright SmallCap Momentum ETF59,555US$1.1M−10,666May 31, 2026
iShares Core S&P Total U.S. Stock Market ETF58,553US$1.49M+25,132Jun 30, 2026
ALPS Medical Breakthroughs ETF55,332US$1.02M+7,490May 31, 2026
Fidelity Total Market Index Fund55,143US$1.01MNo changeMay 31, 2026
Master Small Cap Index Series53,267US$1.35M+15,063Jun 30, 2026
Vanguard Health Care Index Fund47,733US$878K−414May 31, 2026
Fidelity Enhanced Small Cap Core ETF45,975US$1.17MNo changeJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares45,855US$1.44M−5,992Jul 31, 2026

This page holds 50 of 173 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Moulder Leon O Jr
Director, Officer: Chief Executive Officer
Buy60,000USD 16.88US$1.01MMay 18, 2026
Moulder Leon O Jr
Director, Officer: Chief Executive Officer
Buy35,000USD 17.62US$617KApr 29, 2026
Moulder Leon O Jr
Director, Officer: Chief Executive Officer
Buy25,000USD 18.02US$451KApr 28, 2026
Lu Hongbo
Director
Buy3,768USD 18.63US$70,198Mar 31, 2026
Kiselak Tomas
Director
Buy150,000USD 20.00US$3MMar 31, 2026

Big stakes

HolderStakeSharesDate
FMR LLC14.30%7.65MDec 31, 2025
Wellington Management Group LLP12.40%8.09MSep 30, 2026
InnoCare Pharma Inc.10.40%7MAug 26, 2026
SR One Capital Management, LLC7.70%5.04MAug 13, 2026
MOULDER LEON O JR5.09%3.22MApr 29, 2026
BlackRock, Inc.5.00%3.29MSep 30, 2026
Enavate Sciences Gp, LLC4.90%3.25MAug 19, 2026
Patrick G. Enright4.90%2.63MOct 9, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Patrick G. Enright
Other companies: Veradermics, Incorporated (Board Member · Since at least Feb 3, 2026); BioAge Labs, Inc. (Director · Since at least Sep 25, 2024); Vera Therapeutics, Inc. (Managing Director, Longitude Capital · Since at least May 13, 2021); Jazz Pharmaceuticals plc (Managing Director, Longitude Capital · Since at least Jul 7, 2009); Aptinyx Inc (Director · Jun 20, 2018 – May 26, 2022 · Past); Aimmune Therapeutics Inc (Director · Aug 5, 2015 – Oct 10, 2020 · Past); Esperion Therapeutics, Inc. (Director · Jun 25, 2013 – May 14, 2015 · Past); Corcept Therapeutics Incorporated (Director · Mar 25, 2008 – Mar 16, 2017 · Past); Sequenom Inc (Director · Jun 6, 2006 – Jun 22, 2007 · Past); Threshold Pharmaceuticals Inc (Director · Mar 3, 2006 – Feb 28, 2007 · Past)
Board Member · Since at least Sep 12, 2024
Peter Harwin
Other companies: Alaunos Therapeutics, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Oct 13, 2026); Damora Therapeutics, Inc. (Chairman of the Board · Since at least Nov 10, 2025); Crescent Biopharma, Inc. (Chair of Board · Since at least Jun 13, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Cogent Biosciences, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Jul 6, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Jan 22, 2024 · Past); Viridian Therapeutics, Inc. (Director · Oct 27, 2020 – Jun 26, 2024 · Past)
Director · Since at least Sep 12, 2024
Christy Oliger
Other companies: Bicara Therapeutics Inc. (Director · Since at least Jul 28, 2026); Nuvalent, Inc. (Director · Since at least Jun 18, 2025); LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Vera Therapeutics, Inc. (Director · Since at least Jun 7, 2024); Replimune Group, Inc. (Director · Since at least Dec 1, 2021); Karyopharm Therapeutics Inc. (Director · Since at least Aug 28, 2020); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Sierra Oncology Inc (Director · Jun 2, 2021 – Jul 1, 2022 · Past); Reata Pharmaceuticals Inc (Director · Apr 15, 2021 – Sep 26, 2023 · Past)
Director · Since at least Aug 13, 2026
Tomas Kiselak
Other companies: Cyclerion Therapeutics, Inc. (Chairman · Since at least Apr 1, 2026); Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); Spyre Therapeutics, Inc. (Director · Since at least Jun 22, 2023); Viridian Therapeutics, Inc. (Director · Since at least Oct 27, 2020); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – Sep 27, 2024 · Past)
Director · Since at least Sep 12, 2024
John Orloff
Other companies: Alexion Pharmaceuticals Inc (EVP, Research & Development · Jun 5, 2017 – Jul 21, 2021 · Past); Novelion Therapeutics Inc (Director · Nov 29, 2016 – Aug 9, 2018 · Past); Aegerion Pharmaceuticals Inc (EVP, Research and Development · Nov 1, 2016 – Nov 1, 2016 · Past); Baxalta Inc (See Remarks · Jun 30, 2015 – Jun 3, 2016 · Past)
Board Member · Since at least Sep 12, 2024
Leon O Moulder Jr
Other companies: Zai Lab Ltd. (Director · Since at least Jan 1, 2021); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – May 23, 2024 · Past); Trevena, Inc. (Director · May 16, 2018 – Jun 15, 2023 · Past); Tesaro Inc (Chief Executive Officer, Director · Mar 1, 2018 – Jan 22, 2019 · Past)
See Remarks, Director · Since at least Sep 12, 2024
Patricia Allen
Other companies: Kineta Inc. (Director · Dec 22, 2020 – Jun 2, 2021 · Past); Deciphera Pharmaceuticals LLC (Director · Sep 27, 2017 – Jun 11, 2024 · Past); Larimar Therapeutics, Inc. (Chief Financial Officer · Jun 18, 2014 – Jan 22, 2019 · Past); Alnylam Pharmaceuticals, Inc. (VP of Finance and Treasurer · Jan 1, 2006 – Dec 8, 2010 · Past)
Director · Since at least Sep 12, 2024
Hongbo Lu
Other companies: Arrowhead Pharmaceuticals, Inc. (Director · Since at least Mar 15, 2024); Terns Pharmaceuticals, Inc. (Director · Since at least Feb 4, 2021); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Apr 22, 2019 · Past)
Board Member · Since at least Sep 12, 2024
James Boylan
Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Oct 10, 2024); Immunome, Inc. (Director · Since at least Oct 2, 2023); Compass Therapeutics, Inc. (Director · Since at least Nov 4, 2022)
Director · Since at least Sep 12, 2024
Jason Raleigh Nunn
Other companies: Addex Therapeutics Ltd (Director · Since at least Mar 18, 2026); Regulus Therapeutics Inc (Director · Since at least Jun 6, 2019); Trevena, Inc. (Director · May 16, 2019 – Jun 13, 2024 · Past)
Director · Since at least Sep 12, 2024
All 24 people
PersonSeat
Jennifer Fox
Other companies: Apogee Therapeutics, Inc. (Director · Since at least Jul 13, 2023); ProKidney Corp. (Director · Since at least Jul 11, 2022); Nuvation Bio Inc. (Chief Financial Officer · Feb 10, 2021 – Feb 28, 2023 · Past)
See Remarks · Since at least Sep 12, 2024
Joseph L Farmer
Other companies: Tesaro Inc (Sr VP, Gen Counsel & Secretary · Mar 30, 2015 – Jan 22, 2019 · Past); AMAG Pharmaceuticals Inc (General Counsel, SVP · May 22, 2006 – Feb 24, 2012 · Past)
See Remarks · Since at least Sep 12, 2024
Lisa von Moltke
Other companies: Tvardi Therapeutics, Inc. (Director · Nov 1, 2022 – Jun 4, 2024 · Past); Seres Therapeutics, Inc. (See Remarks · Apr 6, 2020 – Feb 15, 2025 · Past)
Head of Research and Development and Chief Medical Officer · Since at least Mar 17, 2025
Jake Nunn
Other companies: Addex Therapeutics Ltd (Director · Since at least Jun 5, 2026)
Board Member · Since at least Nov 4, 2026
Lonnie Moulder
Other companies: Zai Lab Ltd. (Board Member · Since at least Nov 5, 2026)
Chief Executive Officer and Chairman of the Board of Directors · Since at least Aug 13, 2026
Matthew Osborne
Other companies: Cogent Biosciences, Inc. (Chief Financial Officer · Jun 24, 2019 – Feb 11, 2020 · Past)
Investor Relations and Corporate Communications · Mar 17, 2025 – Nov 4, 2026 · Past
Orlando Oliveira
Other companies: Tesaro Inc (SVP & GM, International · Feb 23, 2017 – Jan 22, 2019 · Past)
See Remarks · Since at least Sep 12, 2024
Caroline ChevalierChief Administrative Officer · Since at least Nov 4, 2026
Haley LakenChief Scientific Officer · Since at least Apr 7, 2025
Heinrich SchliekerChief Technical Officer · Since at least Nov 4, 2026
Jerald KornChief Legal & Strategy Officer · Since at least Nov 4, 2026
Joe FarmerPresident and Chief Operating Officer · Since at least Aug 13, 2026
Ting XiaoDirector · Sep 12, 2024 – Feb 7, 2025 · Past
Zenas BioPharmaRoyalty Pharma Investor Relations and Communications · Sep 2, 2025 – Nov 4, 2026 · Past

Open People

Log in to ask 6ix AI your own questions about Zenas BioPharma, Inc.